LB Pharmaceuticals Inc Common Stock (LBRX) Stock

LB Pharmaceuticals Inc Common Stock (LBRX) is a Healthcare stock trading at $30.00 (as of 2026-06-18), with a market capitalization of $802.09M and a trailing P/E of 2.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

Valuation — source: SEC EDGAR (first-party)

Price	$30.00
Market Cap	$802.09M
P/E Ratio	2.7
EV / EBITDA	-13.9
Price / Book	2.27
Price / Sales	131.67
DCF Value (model)	$-12.18
DCF Upside vs Price	-140.6%

Profitability & Growth — source: SEC EDGAR

Revenue (TTM)	$3.92M
Net Margin	-643.0%
Return on Equity	-10.3%
Current Ratio	35.68
Revenue Growth (YoY)	127.8%
EPS Growth (YoY)	-98.2%
FCF Growth (YoY)	-34.5%

Financial Health — source: SEC EDGAR

Altman Z-Score

44.73 (safe)

Valuation vs Sector & Industry

Stock P/E	2.7
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-86.9%
vs Industry	-84.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures

Top Institutional Holder	Deep Track Capital, LP ($82.68M)
Institutional Holders Tracked	10

Company

Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Heather D. Turner
Employees	16
Country	US
IPO Date	2025-09-11

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• SELLAS Life Sciences Group, Inc. (SLS)
• Corvus Pharmaceuticals, Inc. (CRVS)
• Evommune, Inc. (EVMN)
• Alto Neuroscience, Inc. (ANRO)
• Design Therapeutics, Inc. (DSGN)
• Kyverna Therapeutics, Inc. (KYTX)
• Ironwood Pharmaceuticals, Inc. (IRWD)
• Assembly Biosciences, Inc. (ASMB)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.